| abstract |
Anti-IL-17 antibodies are identified which have high affinity and slow off rate for human IL-17. Antibodies of the invention can be chimeric, humanized or fully human antibodies, immunoconjugates or antigen binding fragments of antibodies. The antibodies of the invention are particularly useful for treating autoimmune, inflammation, cell proliferation and developmental diseases. |